In recent years, prospective studies have been conducted to assess the role of prophylaxis and treatment of invasive fungal diseases (IFD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although results of these studies have been encouraging, they have been unable to generate a consensus for optimal prophylaxis and treatment of IFD in the complex scenario of allo-HSCT. A consensus process was undertaken to describe and evaluate current information and practice regarding key questions on IFD management in allo-HSCT recipients; these questions were selected according to the criterion of relevance by group discussion. The Panel produced recommendations for risk stratification, prophylaxis, monitoring, and therapy of IFD and identified top priority issues for further investigation. The definition of the level of risk for IFD associated with the various types and phases of transplantation and the implementation of surveillance and diagnostic strategies are the critical determinants of the antifungal prophylactic and therapeutic approach for allo-HSCT recipients.
In recent years, prospective studies have been conducted to assess the role of prophylaxis and treatment of invasive fungal diseases (IFD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Although results of these studies have been encouraging, they have been unable to generate a consensus for optimal prophylaxis and treatment of IFD in the complex scenario of allo-HSCT. A consensus process was undertaken to describe and evaluate current information and practice regarding key questions on IFD management in allo-HSCT recipients; these questions were selected according to the criterion of relevance by group discussion. The Panel produced recommendations for risk stratification, prophylaxis, monitoring, and therapy of IFD and identified top priority issues for further investigation. The definition of the level of risk for IFD associated with the various types and phases of transplantation and the implementation of surveillance and diagnostic strategies are the critical determinants of the antifungal prophylactic and therapeutic approach for allo-HSCT recipients.
Invasive fungal diseases (IFDs) represent a leading cause of morbidity and mortality among allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . A cohort-retrospective study, conducted during the period 1999-2003 at 11 Italian transplantation centers showed a 7.8% incidence (98 patients) of proven or prob-able invasive fungal infection among 1249 allo-HSCT recipients, with an attributable mortality rate of 72.4% [12] . Aspergillosis accounted for 80% of microbiologically documented infections. This study provides an additional piece of evidence supporting the increasing impact of severe mold infections on the outcome of patients who receive allo-HSCT.
In the past few years, several new antifungal agents have become available, and several prospective studies have been conducted to assess the role of prophylaxis and treatment of IFD in allo-HSCT. Although results of some of these studies were encouraging, taken altogether, they have been unable to generate a consensus for optimal management of IFD in the complex scenario of allo-HSCT.
To improve awareness, diagnosis, and management of IFD in allo-HSCT and to better define the current prophylactic and therapeutic options in clinical practice, a Consensus Development Conference Project was convened. The conclusions of the project were endorsed by the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
DESIGN AND METHODS
Organization. An Expert Panel that included 13 experts was selected on the basis of expertise in research and clinical practice of allo-HSCT. An Advisory Commit- Framing the domain of recommendations. The Expert Panel agreed on the goal of developing recommendations for prophylaxis against and therapy of IFD in allo-HSCT and generated clinical key questions using the criterion of clinical relevance through a Delphi process [13] . The key questions that were considered to be relevant formed the set of questions for the present recommendations.
The consensus process. During the first meeting, each panelist drafted statements that addressed 1 of the preliminarily identified key questions. Subsequently, each panelist scored his or her agreement with the statements made by the other panelists and provided suggestions for rephrasing. To conduct this process, the Expert Panel was convened, and 3 consensus meetings were held in Milan, Italy. The overall goals of the meetings were to reach a definite consensus regarding those question-specific statements for which there was disagreement during the firstround postal phase. The nominal group technique [14] , by which participants were first asked to comment in round-robin fashion on their preliminary votes and then to propose a new vote, was used. If an 80% consensus on the statement was not achieved, the choices were discussed, and a second vote was taken. If an 80% consensus was still not attained, the issue was declared undecidable, and no further attempt was made.
The Expert Panel took note of the recommendations already given by the Infectious Diseases Society of America (IDSA) Guidelines on the basis of evidence from the literature and rated them according to the IDSA standard scoring system [15] [16] [17] . The recommendations that were not clearly supported by literature evidence but were derived from the present consensus process were not rated and were identified as being the result of the Expert Panel opinion (EPO).
RESULTS
The key questions that were considered to be relevant for the present recommendations are the following: risk stratification, prophylaxis, monitoring of patients under prophylaxis, therapy, and research issues.
Risk stratification
Factors that contribute to risk for IFD are summarized in Table 1 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Although neutropenia was historically the major risk factor for IFD, recent studies have demonstrated a reduction in the incidence of neutropenia-related infection and an increase in that of late infection occurring in concomitance with graft versus host disease (GvHD) and reactivation of cytomegalovirus (CMV) infection [11] . Particular settings in which there is an elevated risk for IFD include cord blood transplant (CBT) or T celldepleted HSCT from a human leukocyte antigen (HLA)-haploidentical donor: in these settings, the lack of adoptive transfer of antigen-experienced cells, together with delayed neutrophil engraftment occurring in CBT recipients, favor the development of IFD in the early posttransplantation period [4] [5] [6] [7] [8] [9] .
The Expert Panel discussed stratification of patients according to the risk for IFD associated with different transplant settings and phases, with the aim of planning specific prevention and treatment strategies. ! 0.5 ϫ 10 neutrophils/L) (3) receipt of steroids у2 mg/kg/day for at least 1 week, and (4) recurrent CMV infection requiring ganciclovir therapy (EPO).
Prophylaxis
Prevention strategies for IFD in allo-HSCT recipients are based on environmental precautions and antimicrobial prophylaxis. Although there is general agreement with respect to the environmental precautions, the role of pharmacological prophylaxis is still debated [18] .
Fluconazole (400 mg/daily for adults and 6 mg/kg for children) has been recommended for primary prophylaxis against Candida infection starting from the initiation of the conditioning regimen. The time at which to discontinue fluconazole, however, is more controversial [19] [20] [21] . This prophylactic strategy proved to decrease the rate of Candida infection and was associated with an overall survival benefit at long-term follow-up [21] . However, a major limitation of fluconazole prophylaxis is the lack of activity against molds.
In the past few years, several broadspectrum antifungal drugs have been randomly compared with standard fluconazole for the prophylaxis of IFD in allo-HSCT recipients, with the aim of determining a prophylactic regimen that would also prevent mold infections. Two trials compared intravenous and oral fluconazole with low-dose intravenous amphotericin B (AmB) deoxycolate (administered at a dosage of 0.2 mg/kg once daily or 0.5 mg/kg 3 times per week) [22, 23] . There was no difference with respect to all-cause mortality, fungal-related mortality, and any occurrence of IFD, but fluconazole was significantly better tolerated. No lipid formulation of AmB (LFAmB) has been randomly compared with fluconazole in the prophylaxis of IFD in allo-HSCT. In a recent placebocontrolled trial, inhalation of liposomal AmB (LipAmB) reduced the incidence of pulmonary aspergillosis among neutropenic patients [24] . However, few allo-HSCT patients were included in this study, and no conclusion can be drawn for this population.
Two trials compared the efficacy of intravenous and oral itraconazole with that of intravenous and oral fluconazole in allo-HSCT [25, 26] . Patients who received itraconazole had fewer IFDs caused by Candida glabrata, Candida krusei, and Aspergillus species, although there was no difference in overall or fungal-free survival. Both drugs were well tolerated, but oral itraconazole was associated with treatment discontinuation because of toxicities or gastrointestinal intolerance.
The echinocandin micafungin (50 mg/ day) was compared with fluconazole (400 mg/day) in a double-blind, multicenter trial as prophylaxis against IFD during the pre-engraftment phase [27] . Both drugs were effective for preventing candidiasis, and there was a trend towards the reduction of aspergillosis in favor of patients who received micafungin. The echinocandin was associated with fewer withdrawals from the study due to adverse events.
In a multicenter, double-blind trial involving patients with GvHD, oral posaconazole (600 mg/day) significantly reduced the incidence of IFD and of breakthrough Aspergillus infections, compared with fluconazole [28] . However, there was no difference with respect to all-cause mortality. There was no difference in the prevalence of adverse reactions causing discontinuation of the study drug.
A randomized, double-blind trial of fluconazole versus voriconazole for the prevention of IFD in allo-HSCT showed similar cumulative rates of IFD in the 2 arms (10.6% for fluconazole and 6.6% for voriconazole), although Aspergillus infections were significantly less common among patients who received voriconazole (2.2% vs 5.4%;
). Event-free P p .05 and overall survival rates were similar in both arms [29] .
On the basis of the above studies, international guidelines recommend the use of fluconazole during the engraftment phase and posaconazole during intensive immunosuppressive therapy for GvHD [16, 30] . These key recommendations imply 2 major problems: (1) the lack of any approved mold-active prophylaxis during the engraftment phase, and (2) the lack of an intravenous formulation of posaconazole that could limit its use in patients who are unable to tolerate oral medications, as well as when oral and intestinal mucositis and Occasionally, patients with a previous IFD are referred for an allo-HSCT. Recurrence or progression of an earlier IFD, predominantly due to molds, ranges from 10% to 33% following allo-HSCT, despite secondary antifungal prophylaxis [31] [32] [33] [34] [35] [36] [37] . Few data are available regarding the role of secondary prophylaxis with specific antifungal agents, preventative surgical resection of pulmonary lesions, and prophylactic granulocyte transfusions during neutropenia [32] [33] [34] [35] [36] [37] .
The Expert Panel discussed different transplant types and phases stratified according to their risk for IFD (standard or high) and thus the eligibility of patients for a primary prophylaxis with fluconazole or with a mold-active drug. Finally, the Expert Panel analyzed the role and indications of secondary antifungal prophylaxis.
Recommendations Primary prophylaxis 1. Primary systemic antifungal prophylaxis is recommended for all allo-HSCT recipients and should start together with the conditioning regimen (AI); it should be maintained at least until sustained engraftment, but it is probably appropriate to prolong prophylaxis until day 75 in the absence of acute GVHD (EPO). 2. In patients with severe acute and/or extended chronic GVHD that requires immunosuppressive therapy (who are at high risk for IFD), antifungal prophylaxis should be given regardless of the time from receipt of transplant (AII). 3. In patients at standard risk for IFD in the early phases after transplant, fluconazole (400 mg/day administered intravenously or orally) is the drug of choice for primary prophylaxis (AI), and mold-active drugs are not indicated (EPO). 4. In patients who are at high risk for IFD in the early phases after receipt of the transplant (in particular, adult patients who received haploidentical transplant or CBT), intravenous mold-active antifungal drugs might be considered (EPO). Although intravenous itraconazole or an echinocandin may be used in this setting, LipAmB seems to be a more attractive option, considering its drug interaction profile, antimicrobial spectrum, and local experiences (EPO). 5. Posaconazole (600 mg/day orally) is the drug of choice for patients with GVHD that requires treatment (AI). It should be continued until presumed recovery of the immune status (BIII). 6. A potential limitation of posaconazole is erratic oral absorption, especially in patients with intestinal GVHD and/or diarrhea. In this setting, monitoring of drug levels should be considered (BII). Alternatively, other intravenous mold-active antifungal drugs should be considered (EPO). Secondary prophylaxis 1. Patients with a history of mold infection or invasive candidiasis with organ involvement should receive secondary antifungal prophylaxis from the beginning of conditioning and during the period of severe neutropenia, during immunosuppressive therapy, and/or until immune reconstitution (AIII). 2. No particular antifungal drug can be recommended as secondary antifungal prophylaxis. The choice of the drug should take into account the pathogen responsible for the primary episode, the site of infection, pharmacological considerations, and drug-drug interactions (EPO).
Monitoring of patients who receive antifungal prophylaxis
Surveillance strategies should have a high positive predictive value for early detection of breakthrough IFD and a high negative predictive value for excluding IFD, thus avoiding unnecessary modifications in antifungal prophylaxis. Preemptive antifungal strategies based on predefined surveillance and diagnostic work-up with laboratory markers and radiological findings have been proposed [38] [39] [40] [41] [42] [43] . Both serum Aspergillus galactomannan and panfungal b-glucan assays have been accepted as diagnostic adjuncts for IFD [44] . Galactomannan detection in samples other than serum could be a useful diagnostic tool, but its role has not been standardized to date. 
Antifungal therapy
Empiric antifungal therapy has been widely employed for neutropenic patients, including allo-HSCT recipients. However, fever is a poorly predictive surrogate of IFD and this approach may result in needless, potentially toxic and costly antifungal treatments [48] [49] [50] [51] [52] [53] [54] [55] . These arguments argue against considering fever alone as the indicator for a therapeutic decision and indicate preemptive strategies as an alternative option for patients with early markers suggestive for IFD, but still no evidence of disease [38] [39] [40] 43] . However, in spite of the implementation of antifungal strategies with drugs very active against both yeasts and molds and with a good safety profile, the prognosis of IFD in the allo-HSCT setting continues to be very poor, and the choice of the best antifungal treatment in any single patient remains a crucial problem in the clinical practice. Moreover, immune reconstitution inflammatory syndrome (IRIS) may occur in a subset of patients after allo-HSCT and can be diagnostically challenging. It may play an even greater role leading to a misdiagnosis of antifungal treatment failure. Therapeutic options in microbiologically documented IFD have been well defined in international guidelines [16, 17] . On the contrary, the choice of the best drug for suspected IFD lacking an etiological confirmation, remains a matter of debate. In fact, the so called "broad spectrum antifungal drugs" present different spectrum of activity which may dramatically affect the efficacy of the treatment.
The extremely poor outcome of pa- LipAmB and voriconazole may be considered when the diagnosis is uncertain (EPO). 4. Anticonvulsivant agents that could interact with voriconazole should be avoided (CIII). 5. The use of steroid therapy is not recommended (CIII). Interactions and blood levels 1. Drug level monitoring during prophylaxis with oral azoles should be considered. It is recommended for patients who receive itraconazole, might be useful for those who receive voriconazole, and is probably useful for those who receive posaconazole (BII). The target level for itraconazole is 10.5 mg/mL, although some authors propose a dosage of 10.5 mg/ mL for prophylaxis and of 11 mg/mL for treatment. A voriconazole level of !2.0 mg/mL correlates with failure to respond to therapy, and a level 16 mg/mL correlates with neurological toxicity. For posaconazole, there is currently no accepted target drug concentration; however, some authors have proposed a through posaconazole goal of 0.5-1.5 mg/mL for therapy and 10.5 mg/mL for prophylaxis [59] . 2. Drug-drug interaction may represent a problem that should be recognized and appropriately managed when using a triazole with other drugs that are metabolized within the P450 cytocrome system (Table 2) . To a lesser extent, caspofungin and micafungin also have a potential to interact with some immunosuppressive drugs. 3. Although drug interactions must always be taken into consideration, the (2) prolonged (13 weeks) or recurrent severe neutropenia due to any cause, (3) receipt of steroids у2 mg/kg/day for at least 1 week, and (4) recurrent CMV infection requiring ganciclovir therapy (EPO).
Antifungal prophylaxis
Primary antifungal prophylaxis Primary systemic antifungal prophylaxis is recommended for all patients, should start together with the conditioning regimen (AI), and should be maintained until day 75 (EPO). Fluconazole (400 mg/day intravenously or orally) is the drug of choice for patients at standard risk for IFD in the early phases after transplantation (AI). In patients at high-risk for IFD in the early phases after transplantation, intravenous mold-active antifungal drugs might be considered (EPO). Itraconazole may be effective, but tolerability and drug-drug interactions limit its use (B-I). Although intravenous itraconazole or an echinocandin may be used in this setting, LipAmB may be a more attractive option, considering its drug interaction profile, antimicrobial spectrum, and local experiences (EPO). Posaconazole (600 mg/day orally) is the drug of choice for patients with severe GVHD requiring treatment (AI).
Secondary antifungal prophylaxis
Patients with a history of IFD should receive secondary antifungal prophylaxis from the beginning of conditioning and during the period of severe neutropenia, during immunosuppressive therapy, and/or until immune reconstitution (AIII).
Monitoring of patients under antifungal prophylaxis A surveillance strategy and/or an active diagnostic approach are recommended (EPO). Surveillance is a monitoring strategy for patients who are at high risk but have no signs or symptoms suggestive for a diagnosis of IFD. Active diagnostic approach is defined as a strategy for patients with signs or symptoms and/or microbiologic data possibly related to a fungal infection. In patients at high-risk for IFD, both surveillance and an active diagnostic approach are required. In patients with standard risk for IFD, only an active diagnostic approach is recommended (EPO).
Antifungal therapy
Empirical antifungal therapy Empirical therapy may be administered to persistently febrile and neutropenic patients at high risk for IFD, without signs or symptoms specifically suggestive of an IFD, and who do not respond to 4-7 days of antibacterial therapy (BII). The lack of documentation of IFD in an empirical antifungal approach must follow a proper microbiological and clinical diagnostic effort. The empirical approach cannot be a remedy for an inadequate surveillance and diagnostic strategy (EPO). LipAmB or caspofungin are drugs of choice for empirical therapy (AI).
Preemptive antifungal therapy
Preemptive therapy is an early diagnostic-driven treatment, triggered by the results of a surveillance approach. The choice of the antifungal drug derives from the level of etiological documentation and should consider the spectrum of the drug and the various fungal pathogens possibly involved (EPO).
Therapy for aspergillosis Voriconazole is the drug of first choice for probable and proven invasive aspergillosis, including intracranial localization (AI), and LipAmB can be a suitable alternative (AI). For salvage therapy, agents include lipid formulations of amphotericin B (AII), posaconazole (B-II), itraconazole (B-II), caspofungin (BII), and micafungin (B-II). A combination therapy could be a reliable option for patients with worsening condition as a salvage therapy (BII). The most attractive combination in aspergillus infections includes the use of an echinocandin with either an azole or amphotericin B (EPO). Treatment may be discontinued in patients who have complete resolution of infection and immune recovery (EPO). is recommended during neutropenia and in patients with critical conditions or with deep-seated candidiasis or when the species identification or susceptibility of the pathogen is unknown. Fluconazole (12 mg/kg/day) can be used for patients who are not critically ill and who have had no recent azole exposure (AIII). Candidemia without obvious metastatic complications requires treatment for at least 2 weeks after the last positive blood culture result, but invasive candidiasis may require treatments throughout the duration of residual immunosuppression (AIII). Catheter should be removed whenever possible in every case of candidemia, especially in nonneutropenic patients and when venous line infection is suspected (AII).
Therapy for zygomycosis Initial treatment should be performed using LipAmB B . High dosages (at least 5 mg/kg/day) may be required (EPO). Posaconazole is suitable for long-term suppressive treatment because of its relatively low toxicity and oral administration (EPO).
NOTE.
This table provides a summary of recommendations already provided by the Infectious Diseases Society of America (IDSA) Guidelines [15] [16] [17] and those derived from the Gruppo Italiano Trapianto di Midollo Osseo Consensus. For recommendations already given by the IDSA Guidelines, the rate is reported according to the IDSA grading system for ranking recommendations [15] [16] [17] ; the recommendations not clearly supported by literature evidence but derived from the present consensus process were not rated and were identified as a result of the Expert Panel Opinion (EPO). CBT, cord blood transplant; CMV, cytomegalovirus; GvHD, graft-versus-host disease; HLA, human leukocyte antigen; LipAmB, liposomal amphotericin B.
absence of therapeutic drug monitoring facilities for antifungal drugs should not prevent physicians from using these drugs (EPO). The appropriate duration of monitoring for each drug has not been defined to date.
Research issues
The Expert Panel discussed which important issues deserved top priority for further investigation in allo-HSCT.
1. Adoptive cell therapy and vaccination therapies with dendritic cells aimed at restoring pathogen-specific immunity are attracting the attention of several investigators, and preliminary data obtained from patients who had previously received a T cell-depleted HSCT from an HLAhaploidentical relative and who were given donor-derived CD4 + cell clones that were specifically reactive against Aspergillus antigens has demonstrated the feasibility and partial effectiveness of this approach [60] [61] [62] . 2. Identification of genetic and immunologic tests that are able to document the capacity of certain individuals to efficiently defend against IFD, such as the definition of mannose-binding lectin pathways and toll-like receptor polymorphisms [63] [64] [65] , are warranted for the purpose of tailoring antifungal prophylaxis and duration of therapy. 3. Different approaches to combination therapy for IFD need to be tested in well-conducted, controlled clinical trials.
Conclusions
The existing scientific literature about the management of IFDs in allo-HSCT does not provide strong evidence-based recommendations in the various clinical settings associated with transplantation. Recent guidelines on prophylaxis and treatment of IFD in HSCT recipients offer indications that cannot be extended to different types of transplants and phases of transplantation, and most clinical decisions taken by physicians derive from personal experience and subjective considerations. In the present report, experts in the field judged whether the body of evidence was sufficient to provide any recommendation in a decision process, based on the idea that the risk/benefit ratio for any decision is the result of a partially subjective process. As a consequence, consensus was a critical part of producing the present recommendations. The recommendations already provided by the IDSA Guidelines [15] [16] [17] and those derived from the GITMO Consensus have been summarized in Table 3 .
The definition of the level of risk for IFD, particularly those IFDs caused by molds, associated with the various types of transplant and phases of transplantation and the implementation of surveillance and diagnostic strategies are the critical determinants of the antifungal prophylactic and therapeutic strategies, respectively, in allo-HSCT recipients.
